A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors
In a study comparing the effects of two continuous HRT regimens on cardiovascular risk markers, 43 postmenopausal women were randomly assigned to receive either tibolone 2.5 mg/day ( n=20) or 0.625 mg/day conjugated equine oestrogens plus continuous medroxyprogesterone acetate 5 mg/day ( n=23). Seru...
Gespeichert in:
| Veröffentlicht in: | Atherosclerosis 2002, Vol.160 (1), p.185-193 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 193 |
|---|---|
| container_issue | 1 |
| container_start_page | 185 |
| container_title | Atherosclerosis |
| container_volume | 160 |
| creator | Barnes, Judith F. Farish, Elizabeth Rankin, Marion Hart, David M. |
| description | In a study comparing the effects of two continuous HRT regimens on cardiovascular risk markers, 43 postmenopausal women were randomly assigned to receive either tibolone 2.5 mg/day (
n=20) or 0.625 mg/day conjugated equine oestrogens plus continuous medroxyprogesterone acetate 5 mg/day (
n=23). Serum lipoprotein levels, including LDL and HDL subfractions, oxidisability of LDL and serum nitrate/nitrite levels were determined before and during 12 weeks of therapy. Tibolone significantly reduced triglycerides (17.1%,
P |
| doi_str_mv | 10.1016/S0021-9150(01)00560-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71343577</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021915001005603</els_id><sourcerecordid>71343577</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-5aff2c85738657354b77d70e5bf7135c5f64b79ca927c053e4356d449da4a30f3</originalsourceid><addsrcrecordid>eNqFkE1PJCEQhonR6Kj7E9xw0eihtRiapjmZifErMTFZ9bAnwtCFy253M0K3xn-_ODPRoxcIxVNvVR5CDhicMmDV2QPAlBWKCTgGdgIgKij4BpmwWqqClXW5SSafyA7ZTekvAJSS1dtkhzEphOJyQn7PqA3dwkSfQk-Do8MfpOgc2iEtn28hA_3g-zGMid78eqQRn32Hff7uqTWx8eHVJDu2JtKc8o86Y4cQ0z7ZcqZN-GN975Gnq8vHi5vi7v769mJ2V1iu2FAI49zU1kLyusqHKOdSNhJQzJ1kXFjhqlxS1qiptCA4llxUTVmqxpSGg-N75GiVu4jhZcQ06M4ni21reswr65ySW6TMoFiBNoaUIjq9iL4z8V0z0B9O9dKp_hCmgemlU81z38_1gHHeYfPVtZaYgcM1kD2Y1kXTW5--uDwfFKjMna84zDpePUadrMfeYuNj9q2b4L9Z5T9oL5Ki</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71343577</pqid></control><display><type>article</type><title>A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Barnes, Judith F. ; Farish, Elizabeth ; Rankin, Marion ; Hart, David M.</creator><creatorcontrib>Barnes, Judith F. ; Farish, Elizabeth ; Rankin, Marion ; Hart, David M.</creatorcontrib><description><![CDATA[In a study comparing the effects of two continuous HRT regimens on cardiovascular risk markers, 43 postmenopausal women were randomly assigned to receive either tibolone 2.5 mg/day (
n=20) or 0.625 mg/day conjugated equine oestrogens plus continuous medroxyprogesterone acetate 5 mg/day (
n=23). Serum lipoprotein levels, including LDL and HDL subfractions, oxidisability of LDL and serum nitrate/nitrite levels were determined before and during 12 weeks of therapy. Tibolone significantly reduced triglycerides (17.1%,
P<0.01), HDL cholesterol (22.2%,
P<0.001), and the ratio HDL
2/HDL
3 cholesterol (20.2%,
P<0.01). Total LDL cholesterol levels did not change significantly, although there was a downward trend in the LDLIII subfraction (12.0% reduction;
P=0.06), percentage changes being positively correlated with percentage changes in triglyceride levels (
r=0.60,
P<0.01). Susceptibility of LDL to oxidation was significantly decreased (
P<0.001), changes in lag-time being highly negatively correlated with percentage changes in levels of both LDLIII (
r=−0.68,
P<0.01) and triglycerides (
r=−0.63,
P<0.01). Nitrate/nitrite levels did not change. In contrast, the combined therapy caused a significant reduction in LDL cholesterol levels (11.1%;
P<0.01) as a result of a significant decrease in the LDLI+II subfraction (12.8%;
P<0.05). Changes in LDLI+II and LDLIII were correlated with changes in triglyceride levels (
r=−0.52,
P<0.05 and
r=0.63,
P<0.01, respectively). No other parameter was significantly modified. Between treatment effects were significantly different on triglycerides (
P<0.01), HDL cholesterol (
P<0.001), LDL oxidation (
P<0.01) and LDLI+II:LDLIII ratio (
P<0.05). The reduction in LDL induced by the continuous combined therapy is likely to be beneficial, despite the apparent shift towards the LDLIII subfraction. Changes in oxidisability and subfraction profile of LDL indicate that tibolone may have a more favourable effect on cardiovascular risk than previously suggested.]]></description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/S0021-9150(01)00560-3</identifier><identifier>PMID: 11755937</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ireland Ltd</publisher><subject>Adult ; Biological and medical sciences ; Biomarkers - blood ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - epidemiology ; Cholesterol, HDL - blood ; Cholesterol, HDL - drug effects ; Cholesterol, LDL - blood ; Cholesterol, LDL - drug effects ; Cholesterol, VLDL - blood ; Cholesterol, VLDL - drug effects ; Estrogen Receptor Modulators - therapeutic use ; Estrogen Replacement Therapy ; Estrogens, Conjugated (USP) - therapeutic use ; Female ; Hormones. Endocrine system ; Humans ; LDL oxidation ; LDL subfractions ; Lipoproteins ; Medical sciences ; Medroxyprogesterone Acetate - therapeutic use ; Middle Aged ; Nitrate/nitrite ; Nitrates - blood ; Nitrites - blood ; Norpregnenes - therapeutic use ; Oestrogen/progestogen ; Oxidation-Reduction - drug effects ; Pharmacology. Drug treatments ; Postmenopausal ; Progesterone Congeners - therapeutic use ; Risk Factors ; Tibolone ; Time Factors ; Treatment Outcome ; Triglycerides - blood ; United Kingdom - epidemiology ; Women's Health</subject><ispartof>Atherosclerosis, 2002, Vol.160 (1), p.185-193</ispartof><rights>2002 Elsevier Science Ireland Ltd</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-5aff2c85738657354b77d70e5bf7135c5f64b79ca927c053e4356d449da4a30f3</citedby><cites>FETCH-LOGICAL-c391t-5aff2c85738657354b77d70e5bf7135c5f64b79ca927c053e4356d449da4a30f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0021915001005603$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13430909$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11755937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barnes, Judith F.</creatorcontrib><creatorcontrib>Farish, Elizabeth</creatorcontrib><creatorcontrib>Rankin, Marion</creatorcontrib><creatorcontrib>Hart, David M.</creatorcontrib><title>A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description><![CDATA[In a study comparing the effects of two continuous HRT regimens on cardiovascular risk markers, 43 postmenopausal women were randomly assigned to receive either tibolone 2.5 mg/day (
n=20) or 0.625 mg/day conjugated equine oestrogens plus continuous medroxyprogesterone acetate 5 mg/day (
n=23). Serum lipoprotein levels, including LDL and HDL subfractions, oxidisability of LDL and serum nitrate/nitrite levels were determined before and during 12 weeks of therapy. Tibolone significantly reduced triglycerides (17.1%,
P<0.01), HDL cholesterol (22.2%,
P<0.001), and the ratio HDL
2/HDL
3 cholesterol (20.2%,
P<0.01). Total LDL cholesterol levels did not change significantly, although there was a downward trend in the LDLIII subfraction (12.0% reduction;
P=0.06), percentage changes being positively correlated with percentage changes in triglyceride levels (
r=0.60,
P<0.01). Susceptibility of LDL to oxidation was significantly decreased (
P<0.001), changes in lag-time being highly negatively correlated with percentage changes in levels of both LDLIII (
r=−0.68,
P<0.01) and triglycerides (
r=−0.63,
P<0.01). Nitrate/nitrite levels did not change. In contrast, the combined therapy caused a significant reduction in LDL cholesterol levels (11.1%;
P<0.01) as a result of a significant decrease in the LDLI+II subfraction (12.8%;
P<0.05). Changes in LDLI+II and LDLIII were correlated with changes in triglyceride levels (
r=−0.52,
P<0.05 and
r=0.63,
P<0.01, respectively). No other parameter was significantly modified. Between treatment effects were significantly different on triglycerides (
P<0.01), HDL cholesterol (
P<0.001), LDL oxidation (
P<0.01) and LDLI+II:LDLIII ratio (
P<0.05). The reduction in LDL induced by the continuous combined therapy is likely to be beneficial, despite the apparent shift towards the LDLIII subfraction. Changes in oxidisability and subfraction profile of LDL indicate that tibolone may have a more favourable effect on cardiovascular risk than previously suggested.]]></description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, HDL - drug effects</subject><subject>Cholesterol, LDL - blood</subject><subject>Cholesterol, LDL - drug effects</subject><subject>Cholesterol, VLDL - blood</subject><subject>Cholesterol, VLDL - drug effects</subject><subject>Estrogen Receptor Modulators - therapeutic use</subject><subject>Estrogen Replacement Therapy</subject><subject>Estrogens, Conjugated (USP) - therapeutic use</subject><subject>Female</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>LDL oxidation</subject><subject>LDL subfractions</subject><subject>Lipoproteins</subject><subject>Medical sciences</subject><subject>Medroxyprogesterone Acetate - therapeutic use</subject><subject>Middle Aged</subject><subject>Nitrate/nitrite</subject><subject>Nitrates - blood</subject><subject>Nitrites - blood</subject><subject>Norpregnenes - therapeutic use</subject><subject>Oestrogen/progestogen</subject><subject>Oxidation-Reduction - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Postmenopausal</subject><subject>Progesterone Congeners - therapeutic use</subject><subject>Risk Factors</subject><subject>Tibolone</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Triglycerides - blood</subject><subject>United Kingdom - epidemiology</subject><subject>Women's Health</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1PJCEQhonR6Kj7E9xw0eihtRiapjmZifErMTFZ9bAnwtCFy253M0K3xn-_ODPRoxcIxVNvVR5CDhicMmDV2QPAlBWKCTgGdgIgKij4BpmwWqqClXW5SSafyA7ZTekvAJSS1dtkhzEphOJyQn7PqA3dwkSfQk-Do8MfpOgc2iEtn28hA_3g-zGMid78eqQRn32Hff7uqTWx8eHVJDu2JtKc8o86Y4cQ0z7ZcqZN-GN975Gnq8vHi5vi7v769mJ2V1iu2FAI49zU1kLyusqHKOdSNhJQzJ1kXFjhqlxS1qiptCA4llxUTVmqxpSGg-N75GiVu4jhZcQ06M4ni21reswr65ySW6TMoFiBNoaUIjq9iL4z8V0z0B9O9dKp_hCmgemlU81z38_1gHHeYfPVtZaYgcM1kD2Y1kXTW5--uDwfFKjMna84zDpePUadrMfeYuNj9q2b4L9Z5T9oL5Ki</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>Barnes, Judith F.</creator><creator>Farish, Elizabeth</creator><creator>Rankin, Marion</creator><creator>Hart, David M.</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2002</creationdate><title>A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors</title><author>Barnes, Judith F. ; Farish, Elizabeth ; Rankin, Marion ; Hart, David M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-5aff2c85738657354b77d70e5bf7135c5f64b79ca927c053e4356d449da4a30f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, HDL - drug effects</topic><topic>Cholesterol, LDL - blood</topic><topic>Cholesterol, LDL - drug effects</topic><topic>Cholesterol, VLDL - blood</topic><topic>Cholesterol, VLDL - drug effects</topic><topic>Estrogen Receptor Modulators - therapeutic use</topic><topic>Estrogen Replacement Therapy</topic><topic>Estrogens, Conjugated (USP) - therapeutic use</topic><topic>Female</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>LDL oxidation</topic><topic>LDL subfractions</topic><topic>Lipoproteins</topic><topic>Medical sciences</topic><topic>Medroxyprogesterone Acetate - therapeutic use</topic><topic>Middle Aged</topic><topic>Nitrate/nitrite</topic><topic>Nitrates - blood</topic><topic>Nitrites - blood</topic><topic>Norpregnenes - therapeutic use</topic><topic>Oestrogen/progestogen</topic><topic>Oxidation-Reduction - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Postmenopausal</topic><topic>Progesterone Congeners - therapeutic use</topic><topic>Risk Factors</topic><topic>Tibolone</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Triglycerides - blood</topic><topic>United Kingdom - epidemiology</topic><topic>Women's Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barnes, Judith F.</creatorcontrib><creatorcontrib>Farish, Elizabeth</creatorcontrib><creatorcontrib>Rankin, Marion</creatorcontrib><creatorcontrib>Hart, David M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barnes, Judith F.</au><au>Farish, Elizabeth</au><au>Rankin, Marion</au><au>Hart, David M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>2002</date><risdate>2002</risdate><volume>160</volume><issue>1</issue><spage>185</spage><epage>193</epage><pages>185-193</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract><![CDATA[In a study comparing the effects of two continuous HRT regimens on cardiovascular risk markers, 43 postmenopausal women were randomly assigned to receive either tibolone 2.5 mg/day (
n=20) or 0.625 mg/day conjugated equine oestrogens plus continuous medroxyprogesterone acetate 5 mg/day (
n=23). Serum lipoprotein levels, including LDL and HDL subfractions, oxidisability of LDL and serum nitrate/nitrite levels were determined before and during 12 weeks of therapy. Tibolone significantly reduced triglycerides (17.1%,
P<0.01), HDL cholesterol (22.2%,
P<0.001), and the ratio HDL
2/HDL
3 cholesterol (20.2%,
P<0.01). Total LDL cholesterol levels did not change significantly, although there was a downward trend in the LDLIII subfraction (12.0% reduction;
P=0.06), percentage changes being positively correlated with percentage changes in triglyceride levels (
r=0.60,
P<0.01). Susceptibility of LDL to oxidation was significantly decreased (
P<0.001), changes in lag-time being highly negatively correlated with percentage changes in levels of both LDLIII (
r=−0.68,
P<0.01) and triglycerides (
r=−0.63,
P<0.01). Nitrate/nitrite levels did not change. In contrast, the combined therapy caused a significant reduction in LDL cholesterol levels (11.1%;
P<0.01) as a result of a significant decrease in the LDLI+II subfraction (12.8%;
P<0.05). Changes in LDLI+II and LDLIII were correlated with changes in triglyceride levels (
r=−0.52,
P<0.05 and
r=0.63,
P<0.01, respectively). No other parameter was significantly modified. Between treatment effects were significantly different on triglycerides (
P<0.01), HDL cholesterol (
P<0.001), LDL oxidation (
P<0.01) and LDLI+II:LDLIII ratio (
P<0.05). The reduction in LDL induced by the continuous combined therapy is likely to be beneficial, despite the apparent shift towards the LDLIII subfraction. Changes in oxidisability and subfraction profile of LDL indicate that tibolone may have a more favourable effect on cardiovascular risk than previously suggested.]]></abstract><cop>Amsterdam</cop><pub>Elsevier Ireland Ltd</pub><pmid>11755937</pmid><doi>10.1016/S0021-9150(01)00560-3</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9150 |
| ispartof | Atherosclerosis, 2002, Vol.160 (1), p.185-193 |
| issn | 0021-9150 1879-1484 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71343577 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Biological and medical sciences Biomarkers - blood Cardiovascular Diseases - blood Cardiovascular Diseases - epidemiology Cholesterol, HDL - blood Cholesterol, HDL - drug effects Cholesterol, LDL - blood Cholesterol, LDL - drug effects Cholesterol, VLDL - blood Cholesterol, VLDL - drug effects Estrogen Receptor Modulators - therapeutic use Estrogen Replacement Therapy Estrogens, Conjugated (USP) - therapeutic use Female Hormones. Endocrine system Humans LDL oxidation LDL subfractions Lipoproteins Medical sciences Medroxyprogesterone Acetate - therapeutic use Middle Aged Nitrate/nitrite Nitrates - blood Nitrites - blood Norpregnenes - therapeutic use Oestrogen/progestogen Oxidation-Reduction - drug effects Pharmacology. Drug treatments Postmenopausal Progesterone Congeners - therapeutic use Risk Factors Tibolone Time Factors Treatment Outcome Triglycerides - blood United Kingdom - epidemiology Women's Health |
| title | A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T16%3A39%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20comparison%20of%20the%20effects%20of%20two%20continuous%20HRT%20regimens%20on%20cardiovascular%20risk%20factors&rft.jtitle=Atherosclerosis&rft.au=Barnes,%20Judith%20F.&rft.date=2002&rft.volume=160&rft.issue=1&rft.spage=185&rft.epage=193&rft.pages=185-193&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/S0021-9150(01)00560-3&rft_dat=%3Cproquest_cross%3E71343577%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71343577&rft_id=info:pmid/11755937&rft_els_id=S0021915001005603&rfr_iscdi=true |